Targeted- RNA Alternative to CRISPR
August 21, 2018 | Terry Sharrer
While gene editing focuses on DNA, a lab at The Scripps Research Institute (Jupiter, FL) has paired a small molecule drug, Famaprimir-96, with an RNA degrading enzyme, RNase L, to target a micro RNA that’s highly expressed in triple negative breast cancer. The chimeric drug-enzyme only effects breast tumor cells showing the micro RNA. The researchers, who have computed other chimeras and disease targets believe this could be a safe and effective—perhaps better in both regards than CRISPR-Cas9. MORE
Image Credit: The Scripps Research Institute